CO2020009761A2 - Formas de co-cristales de un análogo de novobiocina y prolina - Google Patents

Formas de co-cristales de un análogo de novobiocina y prolina

Info

Publication number
CO2020009761A2
CO2020009761A2 CONC2020/0009761A CO2020009761A CO2020009761A2 CO 2020009761 A2 CO2020009761 A2 CO 2020009761A2 CO 2020009761 A CO2020009761 A CO 2020009761A CO 2020009761 A2 CO2020009761 A2 CO 2020009761A2
Authority
CO
Colombia
Prior art keywords
forms
novobiocin
crystals
proline
proline analog
Prior art date
Application number
CONC2020/0009761A
Other languages
English (en)
Spanish (es)
Inventor
Xin Jiang
John Allen Walling
Melanie J Bevill
Christopher S Seadeek
Jared P Smit
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CO2020009761A2 publication Critical patent/CO2020009761A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2020/0009761A 2018-02-07 2020-08-06 Formas de co-cristales de un análogo de novobiocina y prolina CO2020009761A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
CO2020009761A2 true CO2020009761A2 (es) 2020-10-30

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0009761A CO2020009761A2 (es) 2018-02-07 2020-08-06 Formas de co-cristales de un análogo de novobiocina y prolina

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR102718111B1 (https=)
CN (2) CN118894894A (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI868593B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276583B2 (en) 2018-02-07 2025-03-01 Reata Pharmaceuticals Inc Crystal structures of proline and a novobiocin analog
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) * 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
WO2013119985A1 (en) * 2012-02-09 2013-08-15 University Of Kansas C-terminal hsp90 inhibitors
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) * 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
HUE052588T2 (hu) * 2014-09-30 2021-05-28 Jiangsu Hengrui Medicine Co Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya
IL276583B2 (en) 2018-02-07 2025-03-01 Reata Pharmaceuticals Inc Crystal structures of proline and a novobiocin analog

Also Published As

Publication number Publication date
JP2026012851A (ja) 2026-01-27
SG11202007530XA (en) 2020-09-29
AR114245A1 (es) 2020-08-12
JP2021512910A (ja) 2021-05-20
CA3090646A1 (en) 2019-08-15
AU2022283638B2 (en) 2024-07-25
CL2020002051A1 (es) 2021-02-19
CN112020506A (zh) 2020-12-01
IL276583B2 (en) 2025-03-01
US20240043465A1 (en) 2024-02-08
US11401294B2 (en) 2022-08-02
CN118894894A (zh) 2024-11-05
KR102718111B1 (ko) 2024-10-17
IL276583A (en) 2020-09-30
IL276583B1 (en) 2024-11-01
JP2024001167A (ja) 2024-01-09
PE20211446A1 (es) 2021-08-05
CA3090646C (en) 2024-02-27
TWI868593B (zh) 2025-01-01
TW202510893A (zh) 2025-03-16
WO2019156907A1 (en) 2019-08-15
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
CA3226385A1 (en) 2019-08-15
IL315865A (en) 2024-11-01
EP3749675A1 (en) 2020-12-16
AU2019217821B2 (en) 2022-09-08
CN112020506B (zh) 2024-10-11
US10717755B2 (en) 2020-07-21
AU2022283638A1 (en) 2023-02-02
US20190241599A1 (en) 2019-08-08
MX2020008326A (es) 2020-09-28
BR112020016205A2 (pt) 2020-12-15
KR20240155354A (ko) 2024-10-28
MY209803A (en) 2025-08-05
TW201945381A (zh) 2019-12-01
EP3749675B1 (en) 2025-12-31
AU2019217821A1 (en) 2020-09-24
MX2022012856A (es) 2022-11-30
NZ767558A (en) 2024-11-29
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CL2022003784A1 (es) 2023-06-09
AU2024227646A1 (en) 2024-11-14
US20200347088A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CL2022003784A1 (es) Formas co-cristalinas de un análogo de novobiocina y prolina
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
NZ629778A (en) C-terminal hsp90 inhibitors
CL2021002959A1 (es) Nuevas formas sólidas de ácido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7- hidroxi-1-propil-1,2,3,4,4a,5,10,10a- octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro2h-piran-2-carboxílico.
MX2019008846A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il) metoxi]-1-piperidil]metil]tiazol-2-il] acetamida como inhibidor de oga.
CO2020003432A2 (es) Molécula de unión al antígeno multiespecífica que tiene actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii) y formulación farmacéutica que contiene tal molécula como ingrediente activo
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
SV2009003305A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MX377532B (es) Sales y formas sólidas de un antibiótico de monobactam.
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
BR112015019412A2 (pt) inibidores de bace1
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
MX2019003310A (es) Inhibidores de dopamina-b-hidroxilasa.
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
BR112022021976A2 (pt) Composto, e, composição farmacêutica compreendendo um composto
CL2020001461A1 (es) Inhibidores de dopamina–b–hidroxilasa.
BR112022005881A2 (pt) Compostos de benzoxazinona como inibidores duplos de klk5/7
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
EA202190899A1 (ru) АРИЛСУЛЬФОНИЛПИРРОЛКАРБОКСАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АКТИВАТОРОВ КАЛИЕВЫХ КАНАЛОВ Kv3
EP3903806A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY TRPV1 ACTIVITY
AR075903A1 (es) Compuestos de alfa-(sulfonamido)acetamida que incorporan deuterio como inhibidores de la produccion de peptido beta amiloide.